Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100-Reference-Cited by-同舟云学术

Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100

Published:2014-08-12 Issue:6 Volume:111 Page:1241-1248
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Schneider B P,Li L,Shen F,Miller K D,Radovich M,O'Neill A,Gray R J,Lane D,Flockhart D A,Jiang G,Wang Z,Lai D,Koller D,Pratt J H,Dang C T,Northfelt D,Perez E A,Shenkier T,Cobleigh M,Smith M L,Railey E,Partridge A,Gralow J,Sparano J,Davidson N E,Foroud T,Sledge G W

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2014430.pdf

Reference32 articles.

1. Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, Watson D, Eclov RJ, Mefford J, McLeod HL, Friedman PN, Hudis CA, Winer EP, Jorgenson EM, Witte JS, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL (2012) A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res 18 (18): 5099–5109.

2. Barsh GS, Copenhaver GP, Gibson G, Williams SM (2012) Guidelines for genome-wide association studies. PLoS Genet 8 (7): e1002812.

3. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS (2011) RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 29 (32): 4286–4293.

4. Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger GG, Suter TM, Toi M, Parmar M, Laeufle R, Im YH, Romieu G, Harvey V, Lipatov O, Pienkowski T, Cottu P, Chan A, Im SA, Hall PS, Bubuteishvili-Pacaud L, Henschel V, Deurloo RJ, Pallaud C, Bell R (2013) Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 14 (10): 933–942.

5. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2 (5): 401–404.

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Contribution of plasma levels of VEGF-A and angiopoietin-2 in addition to a genetic variant in KCNAB1 to predict the risk of bevacizumab-induced hypertension;The Pharmacogenomics Journal;2024-07-12

2. A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11;Clinical Cancer Research;2024-04-19

3. Germline predictors for bevacizumab induced hypertensive crisis in ECOG-ACRIN 5103 and BEATRICE;British Journal of Cancer;2024-02-12

4. Low Hospital Volume Is Associated with Higher All-Cause Mortality in Black Women with Triple Negative Breast Cancer;Journal of Racial and Ethnic Health Disparities;2023-12-01

5. Adverse events of bevacizumab for triple negative breast cancer and HER-2 negative metastatic breast cancer: A meta-analysis;Frontiers in Pharmacology;2023-01-30